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Abstract
IL-22, a member of the IL-10 cytokine family, accelerates tubule regeneration
upon acute kidney injury, hence we speculated on a protective role also in
chronic kidney disease. We quantified intrarenal IL-22 expression after unilat-
eral ureteral (UUO) in wild-type mice and performed UUO in IL-22 knock-out
animals. Obstruction phenotypic differences between IL22+/+ and IL22/ mice
were assessed by histology, immunohistochemistry, immunofluorescence as well
as western blotting and reverse-transcriptase quantitative PCR ex vivo. Addition-
ally, we performed in vitro experiments using both murine and human tubular
cells to characterize IL-22 effects in epithelial healing. We found increasing IL-
22 positivity in infiltrating immune cells over time upon UUO in wild-type
mice. UUO in IL22/ mice caused more tubular cell injury as defined by
TUNEL positive cells and loss of tetragonolobus lectin staining. Instead, tubular
dilation, loss of CD31+ perivascular capillaries, and interstitial fibrosis were
independent of the Il22 genotype as assessed by standard histology, immunos-
taining, and mRNA expression profiling. In vitro experiments showed that
recombinant human IL-22 significantly enhanced human tubular epithelial cell
proliferation and wound closure upon mechanical injury, and electric cell-sub-
strate impedance sensing studies revealed that recombinant IL-22 sustained
tubular epithelial barrier function upon injury. In contrast, IL-22 had no such
direct effects on human fibroblasts. Together, in progressive kidney remodeling
upon UUO, infiltrating immune cells secrete IL-22, which augments tubular
epithelial integrity and epithelial barrier function, but does not affect vascular
rarefaction or fibrogenesis. We conclude that IL-22 could represent a molecular
target to specifically modulate tubular atrophy.
Introduction
Acute kidney injury (AKI) and its long-term consequence,
chronic kidney disease (CKD), are increasing global
health concerns (Levin et al. 2017; Romagnani et al.
2017). Both AKI and CKD are severe disorders with a
growing number of patients and associated with high
morbidity as well as mortality. While there is a plethora
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of initial injurious triggers (ischemic, toxic, inflammatory,
obstructive injury, etc.), most of these processes lead to
inflammation and cell death, a phenomenon dubbed
“necroinflammation”. Eventually, this leads to progressive
nephron loss and renal scaring/fibrosis, as tubular cells
are replaced by mesenchymal tissue. Consistent with the
central role of immune cells in AKI, we and others have
shown a reno-protective role of IL-22 (Kulkarni et al.
2014; Xu et al. 2014), balancing concurrent detrimental
intrarenal inflammation. Nevertheless, it is unknown
whether IL-22 also plays a role in subacute or chronic
kidney disease, where typically there is less inflammation.
Interleukin-22 (IL-22) is a member of the IL-10 family
of cytokines produced by several subsets of lymphocytes
such as T helper (Th) 17 cells, NKT cells, cdT cells, and
innate lymphoid cells (ILCs) (Dudakov et al. 2015;
Weidenbusch et al. 2015). It has been proven that IL-22
is expressed constitutively in a broad array of tissues,
including thymus, brain, gut, skin, spleen, pancreas, liver,
lung and kidney (Weidenbusch et al. 2017). IL-22 binds
to a class II cytokine receptor (IL-22R) composed of IL-
22RA1 and IL-10RB2 subunits leading to the activation of
signal transducer and transcription factor 3 (STAT3)-
dependent downstream signaling pathways (Li et al.
2004). IL-22R is mainly expressed by epithelial cells in a
variety of parenchymal organs, but absent on immune
cells, hence establishing a means of “immune-epithelial”
signaling. In general, IL-22 acts on epithelia cells to
enhance epithelial barrier functions, is involved both in
tissue homeostasis as well as wound healing/tissue repair.
Unilateral ureteral obstruction (UUO) reproduces
obstructive nephropathy in humans including tubular
epithelial cell loss, immune cell infiltration, and interstitial
fibrosis (Ucero et al. 2014; Guiteras et al. 2017; Liu et al.
2017; Qiao et al. 2017; Xiao et al. 2017). Furthermore,
UUO mimics the morphological features of CKD progres-
sion in terms of progressive nephron loss, kidney atrophy,
and renal scaring.
We hypothesized that intrarenal leukocyte-derived IL-
22 would augment tubule integrity also in progressive
obstructive nephropathy. To test this concept, we
employed a series of in vitro and in vivo studies including
UUO surgeries in Il22-deficient mice and experiments
with recombinant IL-22 and human or murine renal
parenchymal cells.
Material and methods
Animal experiments
Il22-deficient mice in the BALB/cJ genetic background
were generated by Genentech as described (Zheng et al.
2007). BALB/cByJ wild-type mice were obtained from
Charles River (Sulzfeld, Germany) as controls. All mice
were housed under SPF conditions in groups of 5 mice in
filter top cages with a 12-h dark-light cycle and unlimited
access to food and water. Cages, nestles, bedding, food,
and water were autoclaved for sterilization before use.
UUO was performed in 8–12 weeks old, sex- and age-
matched wild-type and Il22-deficient mice. After general
anesthesia, the ureteric obstruction was performed by
ligating the left distal ureter with 4-0 Mersilene suture
through a low midline abdominal incision and unob-
structed contralateral kidneys were used as intraindividual
controls as described(Higgins et al. 2003; Skuginna et al.
2011). Mice were sacrificed in deep anesthesia by cervical
dislocation and both sides of the kidneys were harvested
at 1 day, 5 days or 10 days (n = 5–7 in each group) after
UUO surgery. Kidneys were then cut into three pieces,
using one part each for histological, western blotting, and
gene expression analyses. All experiments were conducted
according to German animal protection laws and had
been approved by the local government authorities.
Histological evaluation
Kidneys were fixed in 4% neutral-buffered formalin and
embedded in paraffin. 2 lm sections were used for Silver
stains and immune staining as described (Mulay et al.
2012). Kidney injury and fibrosis were identified by silver
staining (Bio-Rad, California, USA). CD31 (Dianova
GmbH, Hamburg, Germany) staining was used to
demonstrate the presence of endothelial cells in kidney
sections.
L. tetragonolobus lectin (Vector Labs, California, USA)
stainings were used to quantify proximal renal tubular cell
mass and terminal-deoxynucleotidyl transferase-mediated
digoxigenin-deoxyuridine nick-end labeling (TUNEL)
(Roche, Mannheim, Germany) staining was performed to
show cell death. For colocalization studies, aquaporin 1
(Millipore, Burlington, USA) and aquaporin 2 (Abcam,
Cambridge, United Kindom) stainings were co-stained
with TUNEL to distinguish between proximal and distal
tubular cell death. IL-22 stainings were performed as
described at different time points after UUO. The extent
of tubular injury and interstitial fibrosis was assessed by
digital morphometry in ImageJ. To this end, a grid con-
taining 120 (12 9 10) sampling points was used. Grid
points overlying the tubular lumen (tubular dilation),
atrophic or necrotic tubular cells (tubular cell injury) and
interstitial matrix were counted and expressed as a per-
centage of all sampling points. For CD31 staining, Lectin
staining and TUNEL staining, threshold from ImageJ was
used to quantify the percentage of positive area per side.
For IL-22 staining, positive cells in the fields were
counted. 9 fields from each kidney were randomly
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selected. All assessments were performed by an observer
blinded to the experimental condition.
Mouse total RNA isolation, cDNA
preparation, and real-time quantitative
RT-PCR
Mouse total RNA was isolated from kidneys stored in
RNA later solution after sacrifice and RNA was isolated
from an equal amount of tissue mass using a RNA
extracting kit (life Technologies, Germany) as described
(Sayyed et al. 2010; Weidenbusch et al. 2017). RNA con-
centrations were measured with NanoDrop 1000 Spec-
trophotometer. After quantification, RNA quality was
assessed via MOPS gels. From isolated RNA, cDNA was
prepared by Superscript II reverse transcription (Thermo
Fisher) following the manufacturer’s instructions as
described (Lech et al. 2012). Real-time quantitative RT-
PCR was performed using SYBRGreen PCR master mix
and analyzed with a Light Cycler 480 (Roche Diagnostics)
as described. All gene expression values were normalized
by 18s rRNA as a housekeeping gene. Double distilled
H2O was used as negative control for target and house-
keeper genes. All primers were purchased from Metabion
(Metabion, Planegg, Germany) and sequences are listed in
Table 1.
Protein isolation and western blotting
Total protein was extracted from tissue lysates and pro-
cessed for Western blotting using RIPA buffer (Sigma-
Aldrich, Taufkirchen, Germany) with protease inhibitors
(Roche Diagnostics, Penzberg, Germany) and phosphatase
inhibitor (Sigma-Aldrich) as described (Mulay et al.
2012). Briefly, proteins were separated by SDS-PAGE and
transferred to a polyvinylidene difluoride membrane. To
avoid nonspecific binding, membranes were blocked for
2 h at room temperature with 5% BSA in Tris-buffered
saline buffer. Membranes were then incubated overnight
at 4°C with primary rabbit antibodies against mouse Bad,
p-Akt, Stat3, p-stat3 and b-actin (Cell Signaling Technol-
ogy, Danvers, USA). After washing, membranes were
incubated with peroxidase-conjugated anti-rabbit IgG sec-
ondary antibodies (Cell Signaling) in Tris-buffered saline
buffer and staining was visualized by an enhanced chemi-
luminescence system (GE Healthcare, Pittsburgh, USA).
Staining intensity was quantified using ImageJ.
Cell culture
The HK2 cell line and K4 cell line were cultured under
sterile conditions at 37°C and 5% CO2 in medium con-
sisting of DMEM (Gibco/Life Technologies, Grand Island,
NY, USA), 10% fetal bovine serum (FBS) (Biochrom,
Berlin, Germany) and 1% penicillin/streptomycin (PAA
Laboratories, Pasching, Austria).
Metabolic activity assay
The MTT assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide was performed on HK2 cells and
K4 cells to evaluate the metabolic activity induced by
IL-22. Cells were seeded at 5000 cells/well in a 96-well
microculture plate. After cell adhesion for 4 h, various
concentrations of recombinant human IL-22 (rhIL-22)
(Immunotools, Friesoythe, Germany) 1 ng/mL, 10 ng/mL
and 50 ng/mL in serum-free media were added to the
wells followed by continuous incubation for 48 h. Cells
treated with serum-free medium only or 10% FBS sup-
plemented media served as negative and positive con-
trols, respectively. Then, 15 lL MTT (5 mg/mL)
(Promega, Wisconsin, USA) was added to each well and
the plate was incubated at 37°C for another 3 h, after
which 100 lL 10% HCl-SDS was added to each well.
Table 1. Murine primer sequences.
Murine Forward (50-30) Reverse (50-30)
18s GCAATTATTCCCCATGAACG AGGGCCTCACTAAACCATCC
CASP1 TCAGCTCCATCAGCTGAAAC TGGAAATGTGCCATCTTCTTT
CASP8 ATGGCTACGGTGAAGAACTGC TAGTTCACGCCAGTCAGG
COL1A1 ATGTTCAGCTTTGTGGACCTC TCATAGCCATAGGACATCTGG
FADD CACACAATGTCAAATGCCACCTG TGCGCCGACACGATCTACTGC
KIM1 TGGTTGCCTTCCGTGTCTCT TCAGCTCGGGAATGCACAA
IL22 TGGGATTTGTGTGCAAAAGCA TAATTTCCAGTCCTGTCTTCTG
NGAL ATGTCACCTCCATCCTGG GCCACTTGCACATTGTAG
SSeCKs TGAAGCAATCCACAGAGAAGC CTCATCAAACACTTCCGTTGC
TIMP2 GCAACAGGCGTTTTGCAATG AGGTCCTTTGAACATCTTTATCTGC
Transgelin AGCGGACACTAATGAACCTGGG ACTGGTTGTCCGAGAAGTTCCG
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The plate was kept at room temperature overnight.
Optical density (OD) was quantified via a 96-well plate
reader to record the absorbance at 570 nm. OD is
shown after normalization to negative controls.
Scratch-induced wound healing assay
HK2 cells and K4 cells were seeded and cultured in 6-well
plates until the wells were confluent with monolayer cells.
Then artificial wounds were created with a pipette tip and
rinsed twice with PBS to remove the floating cells as
described (Kulkarni et al. 2014). rhIL-22 was added to
the cells at different concentrations (1 and 10 ng/mL).
Cells treated with medium served as negative controls
and treated with 10% FBS served as positive controls.
Two pictures per wound were taken on a phase contrast
microscope at different time points (0, 12, 24 h). Varia-
tions in wound width were analyzed using Image J soft-
ware.
Epithelial barrier testing via electric cell–
substrate impedance sensing (ECIS)
1 9 105 HK2 cells/well were seeded into ECIS 8-well
arrays (8W1E) (Ibidi, Martinsried, Germany) in serum-
free DMEM overnight in the incubator at 37°C. For pri-
mary cell experiments, 4x104 murine isolated primary
tubular cells were seeded in ECIS arrays with medium
including 10% FBS. Capacitance provides an overall mea-
sure of electrode coverage, therefore the value of capaci-
tance is stable at confluence. Wound healing assays were
started after confirming confluence by microscopy as well
as stable capacitance at 64,000 Hz. We analyzed two types
of wound healing assays in HK2 cells. Electric damage
was caused by the application of 3 mA at 60 kHz for
60 sec, and the electric fence for growth inhibition was
executed every 5 min. Isolated murine primary tubular
cells were stimulated with PBS or 20 lg/mL histones at
confluency. Six hours later, histones were washed off by
exchanging medium, then 1 ng/mL of rmIL-22 or PBS
was added to each well. The value of capacitance just
before adding histone and immediately after medium
exchange was set as 0 or 1, respectively.
Statistics
Data are expressed as mean  SEM, unless specified
otherwise in the figure legend. For statistical analysis,
one-way ANOVAs were performed for between group
comparisons with post hoc Bonferroni adjustments for
multiple comparisons were appropriate. All statistic tests
were performed by Prism 6. Significance was assumed at
P < 0.05.
Results
IL-22 expression during CKD development
after UUO surgery
To explore the changes of IL-22 expression in the course of
chronic kidney disease, we performed renal IL-22 immuno-
histochemical staining 1 day, 5 days and 10 days upon
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UUO in BALB/c mice. While kidney sections from IL-22
KO mice showed no IL-22 signal (negative control), a few
IL-22 positive cells were observed in the interstitial com-
partment of kidneys of healthy BALB/c mice. Interestingly,
IL-22 positive cells accumulated in the interstitium of
obstructed kidneys in a time-dependent manner (Fig. 1A).
To assess whether the changes of intrarenal IL-22 expres-
sion were strain-specific, we performed RT-qPCR for IL-22
mRNA expression in C57Bl/6 mice 10 days after UUO.
Again, a significant upregulation of IL-22 was found
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Figure 2. Histopathological changes after UUO in IL22+/+ and IL22/ mice. (A) Representative sections and (B) morphometric scores on
tubular dilatation, tubular injury and interstitial fibrosis in IL22+/+ and IL22/ mice after UUO. *** P < 0.001.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 16 | e13817
Page 5
M. Weidenbusch et al. IL-22 in UUO
(Fig. 1B). We concluded that IL-22 expression increases
along with kidney injury and atrophy in the UUO model.
Il22 deficiency increases tubular injury upon
UUO, but does not affect tubular dilation
and interstitial fibrosis
After left-sided UUO, all mice macroscopically developed
hydronephrosis with progressive renal pelvis dilation and
thinning of renal parenchyma (not shown). Upon
histopathological evaluation by silver staining, we found
tubular injury (as indicated by tubular flattening or
karyorrhexis) to be significantly increased in Il22-deficient
mice at both 5 days and 10 days after UUO surgery com-
pared to wild-type mice (Fig. 2A and B). Of note, no differ-
ences in tubular dilation or interstitial fibrosis were detected
between knock out and wild-type mice (Fig. 2A and B). We
concluded that IL-22 specifically protects tubular epithelial
cells from UUO-induced chronic injury. To further corrobo-
rate this hypothesis, we next sought to quantify gene expres-
sion changes in UUO kidneys of both Il22/ and Il22+/+
mice by means of RTqPCR. Consistent with the histopatho-
logical findings, markers of tubular injury, such as kidney-
injury molecule-1 (Kim1), neutrophil gelatinase-associated
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lipocalin (NGAL), insulin-like growth factor-binding pro-
tein 7 (IGFBP7) and tissue inhibitor of metalloproteinase 2
(TIMP2) were increased in Il22/ compared to Il22+/+ mice
both on day 5 and day 10 after UUO (Fig. 3A), while we
could not detect any significant differences in the expression
of fibrotic markers such as COL1A1, transgelin or SSeCKs
between Il22/ and Il22+/+ mice (Fig. 3B). Taken together,
these data show that Il22 deficiency increases tubular injury
upon UUO, but does not affect tubular dilation and intersti-
tial fibrosis.
Il22 deficiency leads to loss of proximal
tubule cell mass through increased cell
death upon UUO
To further classify the tubular cell phenotype of IL22-defi-
cient animals, we performed Lotus tetragonolobus lectin
staining to quantify proximal tubule cell mass. As shown in
Figure 4A, Lectin positive staining was markedly decreased
in Il22/ mice compared to Il22+/+ mice 10 days post-
UUO (80% vs. 54%, respectively; P < 0.01). Consistent with
increased tubular cell death, there was an increase in
TUNEL+ cells observed in Il22/ mice compared to Il22+/+
mice (Fig. 4B). Next, we performed TUNEL co-stainings
with AQP1 and AQP2 to localize proximal and distal tubules
in Il22+/+ mice, respectively. Interestingly, TUNEL positivity
colocalized with AQP1+ proximal tubules exclusively, indi-
cating that indeed increased cell death after UUO was the
cause of the marked loss of proximal tubule cell mass in
Il22/ animals (Fig. 4C). As TUNEL positivity is not truly
specific for apoptosis (as previously thought), we performed
additional gene expression analysis for FADD, CASP8 and
CASP1 (Fig. 4D). All markers showed marked increases in
Il22/ mice compared to Il22+/+ mice, corroborating the
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finding of increased tubular cell demise and subsequent
tubular atrophy upon UUO in the absence of IL-22.
Il22 activates STAT3 and AKT signaling
pathways upon UUO
IL-22 signaling has been shown to involve the down-
stream activation of both STAT3 and AKT pathways.
Indeed we found decreased phosphorylation of both
STAT3 and AKT in UUO kidneys of Il22/ mice vs.
Il22+/+ mice at day 5 (Fig. 5A). Consistent with the
above-mentioned finding of increased cell death in Il22/
 mice, we also found increased protein levels of BAD, a
proapoptotic mediator and known target of pAKT
(Fig. 5B). Taken together, these findings indicate that IL-
22 signaling activates STAT3 and AKT signaling pathways
upon UUO.
Il22 deficiency does not affect the
rarefaction of peritubular microvasculature
upon UUO
To investigate whether IL-22 plays an additional role on
renal endothelium, CD31 staining was performed to
analyze vascular rarefaction, which typically accompanies
interstitial fibrosis in UUO. Compared with contralateral
control kidneys, obstruction of the ureter induced a sig-
nificant reduction in CD31 expression both at 5 days and
10 days postsurgery (Fig. 6), as expected. Nevertheless,
there was no difference of CD31 expression in kidneys
dependent on Il22 genotype, indicating that IL-22 has no
effect on renal endothelial cells.
IL-22 enhances proliferation of human
tubular cells, but not fibroblasts in vitro
To evaluate if the effects of IL-22 seen after UUO in mice
were transferable to human CKD, we performed experi-
ments with human cells in vitro. First, we performed
MTT assays in HK2 cells and K4 cells (human proximal
tubular cell line and human fibroblast cell line, respec-
tively) to evaluate the effect of IL-22 on human cell pro-
liferation. After culturing for 24 h, HK2 cells treated with
each concentration of rhIL-22 proliferated remarkably
compared with the medium group. Nonetheless, this phe-
nomenon was not observed in K4IM cells, revealing that
IL-22 increased proliferation in an epithelial cell type-spe-
cific manner (Fig. 7).
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IL-22 enhances migration,
re-epithelialization and barrier function of
both murine and human tubular epithelial
cells
To mimic epithelial monolayer injury and re-epitheliali-
zation, we performed mechanical scratch assays of HK2
cells and K4 cells in the presence or absence of IL-22. In
HK2 cells, IL-22 enhanced wound closure after 24 h in a
dose-dependent manner (Fig. 8A), while no such effect
was seen in scratch assays with K4 cells (Fig. 8B).
To further characterize the effect of IL-22 on tubular
epithelial cell barrier function, ECIS assays were per-
formed allowing online monitoring of renal epithelial
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monolayers. As described in methods, t1/2 was used to
measure the effect of IL-22 on migration and prolifera-
tion capacities. Consistent with the results of scratch
assays, t1/2 in fence experiments, which mimic wound
closure, was significantly shorter after rhIL-22 treatment
(Fig. 8C, E–H), confirming an IL-22-induced increase in
cell migration and proliferation. To analyze the role of
IL-22 on recovery after injury, electrical damage was exe-
cuted to confluent HK2 cell monolayers. Again, IL-22
treatment shortened t1/2 compared to vehicle (Fig. 8D),
indicating that IL-22 facilitates recovery after injury in
human tubular cells. To further examine the role of IL-
22 on recovery after kidney injury, murine primary
tubular cells were stimulated with histones, which is
released from dying tubular cells after kidney injury,
then directly damages tubular cells, and promotes
inflammation (Allam et al. 2012). The results showed
that cells treated with IL-22 became confluent within
4 h after removal of histones, while cells treated only
with PBS did not show any regrowth during that time
(Fig. 8I–K), suggesting that IL-22 enables recovery after
kidney injury.
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Discussion
We had hypothesized that intrarenal leukocyte-derived
IL-22 would augment tubule integrity in progressive
obstructive nephropathy. Indeed, this study shows that
IL-22+ cells increasingly accumulate in the renal intersti-
tium upon UUO. Furthermore, absence of IL-22 involves
more tubular injury, tubular cell death and tubular atro-
phy, while renal fibrosis remains unaffected in vivo.
Finally, IL-22 specifically promotes the metabolic activity,
reepithelialization, and barrier function of human tubular
epithelial cells, but not fibroblasts in vitro.
It is well known that, upon both acute and chronic
renal injury, leukocyte recruitment to the injured kidney
regulates both inflammation and regeneration (Anders
et al. 2003; Vielhauer et al. 2010; Jang and Rabb 2015).
While multiple leukocyte mediators have been shown to
be involved in inflammatory processes (Vielhauer and
Anders 2009), recently we and others have identified
proregeneratory factors secreted by leukocytes after acute
renal injury (Kulkarni et al. 2014; Xu et al. 2014). This
study now shows the role of one such proregeneratory
factor, namely IL-22, beyond acute kidney injury in
chronic progressive obstructive nephropathy.
IL-22, which is absent from healthy kidneys, is increas-
ingly expressed in the tubulointerstitium of chronically
injured kidneys. Consistent with its known role in epithe-
lial cells of other organs (Radaeva et al. 2004; Hanash
et al. 2012; Pociask et al. 2013) and after acute kidney
injury Kulkarni et al. 2014; Xu et al. 2014), IL-22 acts as
an epithelial cell survival factor in chronic obstructive
nephropathy. Of note, the prosurvival effects of IL-22 are
highly specific on proximal tubular cells, while fibroblasts
are not affected by IL-22. This is in line with the previous
finding of IL22 receptor expression being confined to
epithelial cells, but not immune cells or fibroblasts (Son-
nenberg et al. 2011). These cell-type specific effects of IL-
22 in the kidney disconnect the usually observed tight
connection of tubular atrophy and interstitial fibrosis
(Bohle et al. 1979; Mackensen-Haen et al. 1981; Bohle
et al. 1987).
Our data which link the prosurvival effects of IL-22 on
renal tubular epithelial cells during chronic injury to the
activation of STAT- and AKT-dependent pathways are in
line with findings from other organs (Brand et al. 2006,
2007; Mitra et al. 2012). Also in chronic kidney disease,
involvement of these pathways has been shown (Tang
et al. 2013b; Wiezel et al. 2014). Especially for the case of
EGFR-dependent AKT activation there has been a lot
of controversy: while several studies found amelioration
of kidney injury through AKT activation (Sinha et al.
2004; Chen et al. 2012; Jang et al. 2012; Kalmar-Nagy
et al. 2013; Ghosh et al. 2016; Mohamed et al. 2017),
other studies showed deleterious effects (Bollee et al.
2011; Tang et al. 2013a; Yamamoto et al. 2017). For
example, Yamamoto et al. (2017) found recently that the
inhibition of AKT signaling by the erlotinib lead to ame-
lioration of the phenotype in a rat model of chronic kid-
ney disease. This effect was found to be driven at least
partly via suppression of mesangial cell and macrophage
activation (Yamamoto et al. 2017). The findings of this
study, however, show that IL-22-dependent AKT activa-
tion is beneficial in chronic kidney disease via increasing
tubular cell survival while other cell types are not affected.
Because of its cellular specificity, IL-22 driven AKT acti-
vation which is confined to tubular cells offers new
options for highly specific therapeutical interventions
compared to, for example, erlotinib.
Unfortunately, the UUO model does not allow for the
assessment of systemic effects of uremia and the role of
IL-22 in this context. While usually in CKD both kidneys
are diffusely affected by the underlying pathology, the
contralateral kidney can fully compensate renal function
upon UUO, hence preventing the occurrence of uremia.
Also in this study we did not assess the exact cellular
source of IL-22. While we have previously shown, that
myeloid cells are the source of intrarenal IL-22 produc-
tions, lymphoid cells (such as T cells and ILCs) have been
shown to be the main IL-22 producers in other organs.
Taken together, we show here for the first time a pro-
tective role of IL-22 in chronic obstructive nephropathy.
Specifically, IL-22 augments tubular cell integrity and
epithelial barrier function, but does not affect vascular
rarefaction or renal fibrogenesis. It is tempting to specu-
late that the effects seen in obstructive nephropathy can
be extrapolated to other forms of chronic kidney diseases,
making IL-22 a potential therapeutical option to specifi-
cally target tubular epithelial cells.
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